You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for New Drug Application (NDA): 020219

✉ Email this page to a colleague

NDA 020219 describes LIVOSTIN, which is a drug marketed by Novartis and is included in one NDA. Additional details are available on the LIVOSTIN profile page.

The generic ingredient in LIVOSTIN is levocabastine hydrochloride. There is one drug master file entry for this compound. Additional details are available on the levocabastine hydrochloride profile page.

Summary for 020219

Tradename:	LIVOSTIN
Applicant:	Novartis
Ingredient:	levocabastine hydrochloride
Patents:	0

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SUSPENSION/DROPS;OPHTHALMIC			Strength	EQ 0.05% BASE
Approval Date:	Nov 10, 1993	TE:		RLD:	No

Expired US Patents for NDA 020219

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	LIVOSTIN	levocabastine hydrochloride	SUSPENSION/DROPS;OPHTHALMIC	020219-001	Nov 10, 1993	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.